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Virus from HT-1080 fibrosarcoma cells infected with the human retrovirus XMRV (xenotropic murine
leukemia virus-related virus) can induce rare foci of transformation in rat 208F fibroblasts. Characterization
of three such foci revealed that one produced an acutely transforming virus at a high titer. The virus consists
of a mutant Nras cDNA from the HT-1080 cells inserted into a retroviral vector (added to the HT-1080 cells
as a marker for infection) in place of internal vector sequences. These results show that XMRV can generate
acutely transforming viruses at a low rate, as is typical of other replication-competent retroviruses, and reveal
the potential for transforming virus contamination of retroviral vectors made from transformed cell lines.
XMRV (xenotropic murine leukemia virus-related virus)
has been associated with prostate cancer (19, 20) and chronic
fatigue syndrome (12), although some researchers fail to detect
XMRV in other populations with these diseases (4, 8). XMRV
is found integrated into human genomic DNA from prostate
cancer samples, indicating that it is indeed a human retrovirus
and not a laboratory contaminant (3, 9). Because of the po-
tential role of XMRV in prostate cancer, we previously tested
XMRV for transforming activity in fibroblast and epithelial
cell lines. Although XMRV is a simple retrovirus that does not
carry a host-derived oncogene, there is precedence for trans-
formation by retroviral Env genes (21, 22). However, transfec-
tion of XMRV proviral DNA or viral envelope expression
vectors into 208F rat fibroblasts did not result in transforma-
tion, and infection of most cell types tested with XMRV did
not induce transformation (13). In contrast, infection of 208F
cells with XMRV did result in rare transformed foci suggestive
of oncogene activation by XMRV. Characterization of cells
from three transformed foci produced by infection of 208F
cells with virus from HTX cells (a pseudodiploid subclone of
HT-1080 fibrosarcoma cells [18]) infected with XMRV and the
LAPSN retroviral vector (included as a marker for infection)
revealed that all produced XMRV and that one produced a
highly active transforming virus (13).
Transforming virus structure. To investigate the genesis of
this transforming virus, we amplified genomic DNA from the
208F focus 3 cells, which produce the transforming virus (13),
by using primers that matched both murine leukemia virus
(MLV) and XMRV long terminal repeats (LTRs) (small ar-
rows near LTRs in Fig. 1). In addition to 8- and 5-kb
products corresponding to full-length XMRV and LAPSN,
2.8-kb and 1.3-kb PCR products were obtained. The 1.3-kb
product was sequenced and determined to be XMRV with an
internal deletion from the 5 LTR-tRNA primer binding site
(PBS) junction through bp 784 of the Env gene. The 2.8-kb
product was a recombinant composed of an Nras cDNA
flanked by LTRs from the LAPSN vector (Fig. 1) (GenBank
accession no. GU934326). The recombinant virus included
LAPSN LTRs and 250 bp of the packaging signal (), which
would allow efficient packaging of the virus, as well as the
entire simian virus 40 (SV40) early promoter and neo gene.
The full-length Nras coding region found in the transforming
virus was 98.6% identical to the human Nras sequence
(NM_002524.3) and only 89.8% identical to the rat sequence
(NM_080766.2), showing that the Nras sequence was acquired
from the HTX cells in which the virus was generated, rather
than from the rat 208F cells. In particular, the Nras insert has
the glutamine-to-lysine activating mutation at residue 61
(Nras*), which has been shown to be the mutation responsible
for the transformed phenotype of HT-1080 cells (1, 7, 14).
PCR using primers specific for human Nras confirmed the
presence of this sequence in focus 3 cells and the absence of
this sequence in the parental rat 208F cell line. Both recom-
bination events occurred within short regions of sequence
identity (Fig. 1).
To confirm that the Nras* recombinant virus that we se-
quenced was indeed capable of transforming cells, we inserted
the cloned and sequenced 2.8-kb PCR product between the
LTRs of the pLAPSN plasmid to make pLNras*SN (Fig. 1).
208F cells transfected with pLNras*SN exhibited transformed
foci between 1 and 2 weeks after transfection while no such
foci were observed following transfection with pLAPSN.
We considered the possibility that 208F foci 1 and 2, which
do not produce transforming virus (13), were transformed by
transfer of Nras* cDNA through a retrofection mechanism
(11) that did not generate a recombinant virus. However, PCR
using human Nras-specific primers (small arrows near Nras* in
Fig. 1) did not detect human Nras in DNA extracted from
these two foci or from an additional three transformed foci
generated in 208F cells by virus from XMRV-infected HTX
cells. This shows that these foci were not transformed by trans-
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fer of Nras* from HTX cells and suggests that they were
transformed by retroviral insertional mutagenesis.
Analysis of HT-1080-based retrovirus packaging cells for
production of transforming virus. Retrovirus packaging cells
have been made from HT-1080 and other transformed cell
lines. Such packaging cells are used to make replication-incom-
petent retroviral vectors for laboratory and clinical applica-
tions, and inadvertent production of a transforming virus such
as the one reported here would be problematic, especially for
clinical applications. To test this possibility, we transduced
FLYA amphotropic HT-1080-based packaging cells (2) with
the LAPSN vector, grew the cells in G418 to select for cells
expressing the vector, and assayed virus produced by the cells
for transformation of 208F cells. For the transformation assay,
208F cells seeded the day before at 6  105 per 10-cm-diam-
eter dish were exposed to filtered (0.45-m-pore-size) virus in
the presence of 4 g Polybrene per ml and then were fed every
3 to 4 days for a month with culture medium containing 5%
fetal bovine serum. This assay is identical to the one used
previously to detect transformation by virus from XMRV-in-
fected cells (13). A total of 8 ml of virus from FLYA/LAPSN
cells induced no foci of transformation in four 10-cm dishes.
Staining the cells for alkaline phosphatase (AP) at the end of
the experiment revealed that 30 to 50% of the 208F cells were
AP, showing that they had been transduced by the LAPSN
vector produced by the FLYA/LAPSN cells. However, this rate
is lower than the 95% LAPSN transduction rate observed
using XMRVLAPSN virus from HTX cells (13).
We next tested whether XMRV infection of FLYA/LAPSN
cells might increase virus production from the cells and allow
transformation of 208F cells. FLYA/LAPSN cells, and HTX
cells as a positive control, were exposed to XMRV from 22Rv1
cells (10), the cells were passaged for 2 weeks to allow com-
plete virus spread, and viruses harvested from the cells were
assayed for transformation of 208F cells as described above.
Ten milliliters of virus from FLYA/LAPSNXMRV cells in-
duced no foci in 4 10-cm dishes of 208F cells, while 10 ml of
virus from HTX/XMRV cells induced one transformed focus
in 4 10-cm dishes of 208F cells. About 70% of the 208F cells
exposed to virus from FLYA/LAPSNXMRV cells were AP,
showing that the cells had been infected. Thus, we were unable
to demonstrate transformation by virus from FLYA cells.
However, the rate of 208F cell infection was lower than that
previously observed with virus from HTX/XMRVLAPSN
cells, and even the rate of transformation by the latter virus is
at the border of detectability (13).
Perspective. The acutely transforming virus that we found in
208F cells infected with virus from HTX/XMRVLAPSN
cells arose by recombination between Nras* and LAPSN vec-
tor sequences at short regions of sequence identity. It is gen-
erally assumed that such recombination events are generated
primarily during reverse transcription, because the rate of
DNA recombination at such short regions of homology is ex-
pected to be exceedingly low, while template switching during
reverse transcription is common. Two general models involv-
ing template switching during reverse transcription have been
proposed to explain such recombination events. Following the
model proposed by Zhang and Temin (24), the LAPSN vector
could have integrated upstream of the Nras* gene in the in-
fected HTX cells and recombination could have occurred dur-
ing retroviral reverse transcription after packaging of a read-
through mRNA containing both LAPSN and Nras* sequences.
Alternatively, following the model proposed by Hajjar and
Linial (6), illegitimate packaging of an Nras* mRNA could
have resulted in direct recombination between Nras* and
LAPSN RNA during retroviral reverse transcription. We can
clearly rule out a mechanism involving aberrant splicing of a
read-through transcript because of lack of suitable signatures
of splicing in the LNras*SN virus. Overall, these data demon-
strate that the human retrovirus XMRV is able to mediate the
generation of retroviruses carrying host cell oncogenes.
The LAPSN vector is produced at a 6-fold-higher titer
than is XMRV from HTX/XMRVLAPSN cells (4  107
versus 6.5  106 focus-forming units [FFU]/ml, respectively)
(13), indicating that LAPSN RNA is much more abundant
in virions and providing an explanation for involvement of
LAPSN and not XMRV in recombination with Nras*. The
structure of LNras*SN is reminiscent of the well-known ras-
containing transforming retroviruses, Harvey and Kirsten mu-
rine sarcoma viruses, which were generated in rats infected
with murine leukemia viruses. These independently isolated
viruses contain ras sequences inserted into rat virus-like 30S
(VL30) elements in place of internal VL30 sequences, all
flanked by murine leukemia virus sequences, including their
LTRs (5). Most acutely transforming retroviruses have been
isolated following infection of animals with nontransforming
replication-competent retroviruses, as was the case for the
Harvey and Kirsten murine sarcoma viruses. However, acutely
FIG. 1. Proviral structure of the acutely transforming retrovirus LNras*SN. Retroviral LTR and SV40 transcription start sites are indicated by
large arrows, protein coding regions are shown in black, PolyA indicates the polyadenylation signal in the downstream LTR, and PCR primers are
shown with small arrows. Nras* indicates the mutant human Nras sequence (Gln-to-Lys activating mutation at protein residue 61). Sequences at
the recombination sites are shown at bottom with vertical lines indicating identical bases and underlined bases indicating regions of microhomol-
ogy.
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transforming viruses have also been generated in cultured cells
using various nontransforming replication-competent retrovi-
ruses (15–17, 23), showing that XMRV is not unique in this
regard. Interestingly, production of acutely transforming vi-
ruses was facilitated by growth of the nontransforming parental
viruses in chemically transformed cells or in cultured tumor
cells (16, 17).
LNras*SN appears to be the first example of oncogene ac-
quisition by a retroviral vector during vector replication, and
although we did not detect the production of acutely trans-
forming virus from retrovirus vector-producing packaging cells
made using HT-1080 cells, our general results indicate that this
may happen at some low rate. This possibility should be con-
sidered when vectors are made from packaging cells derived
from tumor cells or cells that express oncogenes, such as pack-
aging cells based on HT-1080, 293, and 293T cells.
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